Oragenics and Intrexon announce encouraging results in lantibiotic testing

Oragenics (OGEN +1.3%) and recent IPO Intrexon (XON -2%) say that collaborative experiments demonstrate a genetically-modified host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.

The collaboration also uncovered two new methods of purifying its lead compound resulting in higher purity and yields of MU1140.

OGEN and XON entered into an Exclusive Channel Collaboration agreement to develop and commercialize lantibiotics for the treatment of infectious diseases in June 2012.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs